Claims
- 1. A method for the therapeutic treatment of a blood clot in, around or attached to an indwelling vascular access device comprising administering through said vascular access device a quantity of fibrinolytic metalloproteinase which does not exceed 1.7 milligrams of fibrinolytic metalloproteinase per kilogram of body weight of the human subject being treated, in a pharmaceutically acceptable solution.
- 2. A method for proteolytically degrading a blood clot in, around or attached to an indwelling vascular access device comprising administering through said vascular access device a quantity of fibrinolytic metalloproteinase that complexes with alpha-two macroglobulin, in an amount sufficient to facilitate lysing of the clot while not exceeding a level significantly above saturable level of alpha-two macroglobulin in said human subject, in a pharmaceutically acceptable solution.
- 3. The method of claim 1 or 2 comprising 0.1 to 80 mg/ml fibrinolytic metalloproteinase.
- 4. The method of claim 1 or 2 comprising 0.1 to 50 mg/ml fibrinolytic metalloproteinase.
- 5. The method of claim 1 or 2 wherein said vascular access device is a catheter.
- 6. The method of claim 1 or 2 wherein said vascular access device is a shunt.
- 7. The method of claim 1 or 2 wherein said vascular access device is an access graft.
- 8. The method of claim 1 or 2 wherein said vascular access device is a needle.
- 9. The method of claim 1 or 2 wherein the vascular access device is used to introduce a liquid composition into a human artery or vein.
- 10. The method of claim 1 or 2 wherein the vascular access device is used to remove blood from a human artery or vein.
- 11. The method of claim 1 or 2 wherein the vascular access device is used in connection with a hemodialysis procedure.
- 12. The method of claim 1 or 2 wherein the vascular access device is used in connection with a blood transfusion procedure.
- 13. The method of claim 1 or 2 wherein the vascular access device is used in connection with chemotherapy.
- 14. The method of claim 1 or 2 which is used to treat peripheral arterial occlusions.
- 15. The method of claim 1 or 2 wherein the vascular access device is used in connection with blood removal.
- 16. The method of claim 1 or 2 wherein said blood clot is located on an interior surface of an indwelling vascular access device.
- 17. The method of claim 1 or 2 wherein said blood clot is located on an exterior surface of an indwelling vascular access device.
- 18. The method of claim 1 or 2 wherein said blood clot is attached to an indwelling vascular access device.
- 19. The method of claim 1 or 2 wherein said vascular access device is located in an artery.
- 20. The method of claim 1 or 2 in which the vascular access device is located in a vein.
- 21. The method of claim 1 or 2 in which said vascular access device comprises a “side hole” catheter device.
- 22. The method of claim 1 or 2 in which said vascular access device comprises a “pressure response outlet” (PRO) catheter delivery device.
- 23. The method of claim 1 or 2 in which the solution of fibrinolytic metalloproteinase is administered by bolus.
- 24. The method of claim 1 or 2 in which the fibrinolytic metalloproteinase comprises Novel Acting Thrombolytic (NAT).
- 25. The method of claim 1 or 2 in which the fibrinolytic metalloproteinase comprises fibrolase.
- 26. A method for restoring patency to an indwelling vascular access device having a fibrin-based occlusion comprising administering through said vascular access device a quantity of a fibrinolytic metalloproteinase that complexes with alpha-two macroglobulin, in an amount sufficient to facilitate lysing of the clot while not exceeding a level significantly above saturable level of alpha-two macroglobulin in said human subject, in a pharmaceutically acceptable solution, wherein said quantity does not exceed 1.7 milligrams of the fibrinolytic metalloproteinase per kilogram of body weight of the human subject being treated.
- 27. A method for restoring function to an indwelling vascular access device having a fibrin-based occlusion comprising administering through said vascular access device a quantity of a fibrinolytic metalloproteinase that complexes with alpha-two macroglobulin, in an amount sufficient to facilitate lysing of the clot while not exceeding a level significantly above saturable level of alpha-two macroglobulin in said human subject, in a pharmaceutically acceptable solution, wherein said quantity does not exceed 1.7 milligrams of the fibrinolytic metalloproteinase per kilogram of body weight of the human subject being treated.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. application Ser. No. 09/466,276, filed Dec. 17, 1999, which is hereby incorporated by reference.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09466276 |
Dec 1999 |
US |
Child |
10177916 |
Jun 2002 |
US |